Orchestra BioMed Holdings, Inc.

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) is a biomedical company focused on developing cardiovascular medical devices, including its BackBeat CNT cardiac neuromodulation therapy for hypertension and its Virtue sirolimus-eluting balloon for coronary artery disease. The company went public through a SPAC merger, with the combined entity beginning to trade under the OBIO ticker on Nasdaq following deal close in early 2023; the blank-check vehicle completed its IPO in 2021. The July 2022 Form 8-K filing, accession number 0001213900-22-041877, was submitted during the pre-close period of the transaction. Orchestra BioMed operates in the medical device and cardiovascular therapeutics sector. For complete filing history, deal terms, and real-time SPAC data on OBIO, sign up for full access at SpacDesk.